Tolerizing Agonist/Immunomodulator Loaded Liposomes for Long-Lived Immune Tolerance



    • A failure of central immune tolerance typically driven by autoantigen specific T regulatory (Treg) cells is the primary cause of many autoimmune diseases.
    • This technology generates antigen specific immune tolerance for autoimmune or transplantation therapy via induction of tolerogenic dendritic cells (tolDC, PD-L1+, CD80- CD11c+)) which facilitate the differentiation of antigen specific Tregs.

    • The invention is a liposome loaded with immunosuppressive drugs, toll-like-receptor (TLR) agonists, and any antigen of interest.  This unique co-formulation of activating and inhibitory signals generates a potent toIDC phenotype in vivo.



    Tolerogenic Liposomes Prevent EAE Disease Progression via Antigen Specific Bystander Tolerance.
    (A) Mice were treated on day 4 and 5 (following EAE induction), allowed to rest for 48 hrs then treated again on day 7 and 8. After final treatment, mice were monitored for 37 days. (B) Mice were treated similarly, but sacrificed on day 14 following EAE induction. Serum was taken and analyzed for EAE peptide specific IgG levels via ELISA. UT denotes an “untreated” mouse without MOG exposure.




    • Reliable generation of antigen specific Tregs with minimal non-specific immune suppression

    • Long-lived immune tolerance

    • Easy manufacturing and storage



    • Autoimmune diseases
    • Transplant medicine


    • Manuscript under review
    • In vivo experiments performed



    Reference ID

    Have Questions?

    Michael Hinton

    Contact Michael Hinton, Manager, Technology Marketing, who can provide more detail about this technology, discuss the licensing process, and connect you with the inventor.

    This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of products and services, assist with our promotional and marketing efforts.